The Board of Camlin Fine Sciences at its meeting held on 22 November 2024 has approved the following:- The revision of the quantum of the proposed Rights Issue to an amount not exceeding Rs. 225 crore;- The proposal for fund raising by way of issuance of up to 10,000 senior, secured, redeemable, unlisted, unrated, non-convertible debentures of face value of Rs. 100,000 each (NCDs) aggregating for an amount of Rs. 100 crore on a private placement basis. Powered by Capital Market - Live News

Camlin Fine Sciences will hold a meeting of the Board of Directors of the Company on 22 November 2024Powered by Capital Market - Live News

Net Loss of Camlin Fine Sciences reported to Rs 100.23 crore in the quarter ended September 2024 as against net loss of Rs 19.38 crore during the previous quarter ended September 2023. Sales rose 4.21% to Rs 422.97 crore in the quarter ended September 2024 as against Rs 405.88 crore during the previous quarter ended September 2023. ParticularsQuarter EndedSep. 2024Sep. 2023% Var. Sales422.97405.88 4 OPM %10.236.19 - PBDT29.427.12 313 PBT8.73-12.09 LP NP-100.23-19.38 -417 Powered by Capital Market - Live News

Camlin Fine Sciences will hold a meeting of the Board of Directors of the Company on 11 November 2024Powered by Capital Market - Live News

The Board of Camlin Fine Sciences at its meeting held on 10 September 2024 has approved the following:1. Increase in authorised share capital of the Company and subsequent alteration to the Memorandum of Association of the Company. 2. Raising of fund by way of issue of equity shares of the Company of face value Re 1 each through Rights Issue for an amount not exceeding Rs 150 crore. Powered by Capital Market - Live News